49
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T15819 |
LY377604
|
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
LY377604 是一种人类 β3 肾上腺素能受体激动剂(EC50:2.4 nM)和β1/2-肾上腺素能受体拮抗剂,可用于研究肥胖。 | |||
T15815 |
LY3295668
AK-01 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
LY3295668 (AK-01) 是 Aurora A 的选择性抑制剂,对 Aurora A 和 B 的 Kis 分别为 0.8 nM 和 1038 nM。 | |||
T27949 |
LY382884
LY-382884,LY 382884 |
GluR | Neuroscience |
LY382884 是一种具有选择性和有效性的 GLU(K5)受体拮抗剂,具有抗焦虑活性。LY382884可阻断阻断苔藓纤维LTP的诱导。 | |||
T4266 |
LY334370
4-氟-N-(3-(1-甲基哌啶-4-基)-1H-吲哚-5-基)苯甲酰胺盐酸盐,LY 334370 |
5-HT Receptor | GPCR/G Protein; Neuroscience |
LY334370 是一种选择性5-HT1F 受体激动剂,Ki 值为 1.6 nM。 | |||
T27947L |
LY339434 HCl
LY339434 HCl(219566-62-8 Free base) |
GluR; NMDAR | Neuroscience |
LY339434 HCl是一种亲和力很低的GluR5红氨酸受体激动剂。LY339434 HCl 主要通过影响 N-甲基-D-天冬氨酸(NMDA)受体来快速的神经元死亡。 | |||
T61661 |
LY3372689
Formulaic Ia |
Microtubule Associated | Cytoskeletal Signaling |
LY3372689 (Formulaic Ia) 是一种具有口服活性的O-GlcNAcase (OGA)酶抑制剂,可用于包括阿尔茨海默病在内的 tau 蛋白类疾病。 | |||
T5125 |
LY3200882
|
TGF-beta/Smad | Stem Cells |
LY3200882 是一种高度选择性的、口服活性的、具有 ATP 竞争性的 TGF-β 受体 1 型 (ALK5) 抑制剂(IC50:38.2 nM)。它能够抑制多种促肿瘤活性,可用作免疫调节剂。 | |||
T15816 |
LY341495
|
GluR | Neuroscience |
LY341495 是高效的代谢型谷氨酸受体拮抗剂,对多种谷氨酸受体的亚型表现除很高的活性,可用于研究神经系统疾病。 | |||
T27951 |
LY392098
LY-392098,LY 392098,AMPA receptor modulator-3 |
GluR; iGluR | Membrane transporter/Ion channel; Neuroscience |
LY392098 (AMPA receptor modulator-3) 是 AMPA 受体的变构调节剂,EC50 为 4.4 μM,可用于哺乳动物神经系统的研究。 | |||
T2688 |
LY310762
LY310762 HCl |
5-HT Receptor | GPCR/G Protein; Neuroscience |
LY310762 是 5-HT1D 受体拮抗剂,Ki 为 249 nM。 | |||
T9064 |
LY3143921 hydrate
|
CDK | Cell Cycle/Checkpoint |
LY3143921 ((S)-Example 2) hydrate 是一种具有口服活性的 CDC7激酶抑制剂。LY3143921 hydrate 表现出广泛的体外抗癌活性。 | |||
T9078 |
LY3405105
1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester |
CDK | Cell Cycle/Checkpoint |
LY3405105 (1-Piperidinecarboxylic acid, 4-[[5-methyl-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 1-[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]-3-pyrrolidinyl ester) 是一种新型 CDK7 抑制剂。 | |||
T6882 |
LY3009120
DP-4978 |
Raf; Autophagy | Autophagy; MAPK |
LY3009120 (DP-4978) 是一种泛RAF 抑制剂,其抑制BRAFV600E、BRAFWT 和CRAFWT 的IC50分别为 5.8、9.1和15 nM。 | |||
T7810 |
LY3177833
LY-3177833 |
CDK | Cell Cycle/Checkpoint |
LY3177833 抑制CDC7和pMCM2,IC50值分别为 3.3 nM 和 290 nM。 | |||
T78626 |
LY393615
NCC1048 |
Calcium Channel | Membrane transporter/Ion channel; Metabolism |
LY393615 (NCC1048) 是新型神经元 Ca2+ 与 Na+ 通道阻断剂,具备优良的脑渗透性,并在脑缺血模型中显示神经保护效果,适用于神经性疾病研究。 | |||
T60355 | LY367385 hydrochloride | ||
LY367385 hydrochloride 是一种高效且选择性的mGluR1a 拮抗剂,抑制喹喹啉诱导的磷酸肌醇水解的IC50值为 8.8 μM,而对 mGlu5a 的IC50值大于 100 μM。LY367385 hydrochloride 具有神经保护,抗惊厥和抗癫痫作用。 | |||
T18246 |
Mal-C2-Gly3-EDA-PNU-159682
|
Others | Others |
Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), combines the cleavable ADC linker Mal-C2-Gly3-EDA with the potent ADC cytotoxin PNU-159682. | |||
T72384 |
(S)-LY3177833 hydrate
|
||
(S)-LY3177833 ((S)-Example 2) hydrate,是一种具口服活性的CDC7激酶抑制剂,展现了广泛的体外抗癌活性。 | |||
T11911 |
LY3020371 hydrochloride
|
GluR | Neuroscience |
LY3020371 hydrochloride exerts an antidepressant-like signature in vivo. LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM. | |||
T77828 |
Fmoc-Gly3-Val-Cit-PAB
|
||
Fmoc-Gly3-Val-Cit-PAB为一种可降解(cleavable)的ADC linker,其用途在于抗体偶联活性分子(ADC)的合成。 | |||
T70005 |
LY3325656
|
||
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. | |||
T38791 |
LY3020371
|
||
LY3020371 is a highly potent and selective antagonist targeting the glutamate (mGlu) 2/3 receptor, showcasing excellent inhibition at Ki values of 5.26 nM and 2.50 nM for hmGluR2 and hmGluR3, respectively. With its remarkable affinity and specificity, LY3020371 serves as a valuable tool in depression research. | |||
T27947 |
LY339434
LY 339434,LY-339434 |
||
LY339434 is a potent and selective agonist of the kainate receptor GluK1, GluR5. | |||
T39406 |
(±)-LY367385
(±)-LY367385 |
||
(±)-LY367385 is the racemic form of LY367385, and LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 exhibits a high inhibitory activity against quisqualate-induced phosphoinositide (PI) hydrolysis, with an IC50 value of 8.8 μM. In contrast, its inhibitory activity against mGlu5a is greater than 100 μM. | |||
T15818 |
LY367385
|
FXR | Metabolism |
LY367385 is a highly effective and selective mGluR1a antagonist. LY367385 has neuroprotective, anticonvulsant, and antiepileptic effects. Compared with > 100 μM for mGlu5a, LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis. | |||
T27944 |
LY3202626
LY 3202626,LY-3202626 |
||
LY3202626, an amyloid precursor protein secretase (BACE protein) inhibitor, is used for the treatment of Alzheimer's disease. | |||
T60747 |
LY3143921
|
||
LY3143921 ((S)-Example 2) 具有广泛的体外抗癌活性,是口服有效的CDC7激酶抑制剂。 | |||
T18247 |
Mal-C2-Gly3-EDA
|
Others | Others |
Mal-C2-Gly3-EDA is a cleavable antibody-drug conjugate (ADC) linker equipped with a Maleimide moiety. It serves the purpose of facilitating the synthesis of ADCs. | |||
T82384 |
Fmoc-Gly3-VC-PAB-MMAE
|
||
Fmoc-Gly3-VC-PAB-MMAE 是一款用于 ADC 的药物-连接子偶联物,由 MonomethylauristatinE 和连接子构成。 | |||
T33013 |
LY334362
LY 334362,LY-334362 |
||
LY334362 is a bioactive chemical. | |||
T15814 |
LY3130481
|
Others | Others |
LY3130481 is an AMPA receptor antagonist. It is dependent upon transmembrane AMPA receptor regulatory protein (TARP) γ-8 and selectively inhibits AMPA/TARP γ-8 (IC50: 65 nM). | |||
T38790 |
LY3027788 hydrochloride
|
||
LY3027788 hydrochloride is a diester analog of LY3020371, a selective antagonist of the metabotropic glutamate 2 and 3 receptors (mGlu2/3). It serves as a highly potent and orally bioavailable prodrug of LY3020371. Notably, LY3027788 hydrochloride exhibits antidepressant efficacy. | |||
T27943 |
LY314228
LY-314228,LY 314228 |
||
LY314228 is an antagonist of 5-HT2A receptor. | |||
T27950 |
LY389795
LY-389795,LY 389795 |
||
LY389795 is an agonist of group II (mGlu2/3) metabotropic glutamate receptor, it is used in inflammatory pain models. | |||
T62610 |
LY3154885
|
||
LY3154885 是一种口服具有活力的多巴胺 D1 受体正变构调节剂 (PAM)。LY3154885 对药物-药物相互作用 (DDI) 的风险具有改善作用。 | |||
T24422 |
LY3104607
LY 3104607,LY-3104607 |
||
LY3104607 is a G Protein-Coupled Receptor 40 agonist. It is active in oral treatment for patients with type 2 diabetes mellitus and is a glucose-lowering drug candidate. | |||
T40308 |
Gly3-VC-PAB-MMAE
Gly3-VC-PAB-MMAE |
||
Gly3-VC-PAB-MMAE is a chemical compound comprised of a cleavable antibody-drug conjugate (ADC) linker, Gly3-VC-PAB, and a potent inhibitor of tubulin, MMAE. It is utilized in the synthesis of ADCs. | |||
T22951 |
LY320135
LY 320135 |
Others | Others |
CB1 receptor antagonist/inverse agonist | |||
T27942 |
LY307452
LY 307452,LY-307452 |
||
LY307452 is a selective antagonist of mGluR2/3. | |||
T11912 | LY3154207 | Others | Others |
LY3154207 is a subtype selective, potent, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50=3 nM). | |||
T15813 |
LY309887
|
LTR | Immunology/Inflammation |
LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM). It also has antitumor activity. | |||
T27945 |
LY320954
LY 320954,PDSP1_001629,LY-320954 |
||
LY320954 is an antagonist of 5-HT2A receptor. | |||
T27941 |
LY303336
LY-303336,LY 303336 |
||
LY303336 is an antagonist of AT1 receptor. | |||
T27940 |
LY301875
LY 301875,LY-301875 |
||
LY301875 is an antagonist of nonpeptide angiotensin receptor. | |||
T61610 |
NPEC-caged-LY379268
|
||
NPEC-caged-LY379268 是第二组 mGluR 激动剂。 | |||
T38792 |
LY3027788
LY3027788 |
||
LY3027788, a diester analog of LY3020371, an mGlu2/3 receptor antagonist, is a highly potent and orally active prodrug of LY3020371. Notably, LY3027788 exhibits significant antidepressant efficacy. | |||
T63051 |
(R)-MALT1-IN-3
|
||
(R)-MALT1-IN-3 (compound 121) 是一种 MALT1 蛋白酶的有效抑制剂 (IC50: 20 nM),对于 OCI-LY3 细胞中的人 IL6/IL10 的 IC50 值分别为 60 nM 和 40 nM。 | |||
T63053 |
MALT1-IN-3
|
||
MALT1-IN-3 是一种 MALT1 蛋白酶的有效抑制剂 (IC50: 0.06 μM),对 OCI-LY3 细胞中人 IL6 和 IL10 的 IC50 值分别为 0.14 和 0.13 μM。 | |||
T62533 |
MALT1-IN-8
|
||
MALT1-IN-8 是一种 MALT1 蛋白酶的有效抑制剂 (IC50: 2 nM)。MALT1-IN-8 对 OCI-LY3 淋巴瘤细胞的生长具有抑制作用 (IC50: 1.16 μM),表现出抗癌活性。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04925 |
CD8 beta Protein, Human, Recombinant, Biotinylated
LY3,LYT3,CD8b molecule,P... |
Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant, Biotinylated is expressed in HEK293 mammalian cells. The predicted molecular weight is 17.6 kDa and the accession number is P10966-1. | |||
TMPY-02925 |
CD8 beta Protein, Human, Recombinant
LEU2,P37,CD8b molecule,LYT3,CD8B1... |
Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 17.6 kDa and the accession number is P10966-1. | |||
TMPY-02703 |
CD8 beta Protein, Human, Recombinant (hFc)
LYT3,CD8 β,CD8b molecule,LY3<... |
Human | HEK293 Cells |
CD8 beta Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is P10966-1. |